Nanasi Sekona, Ashley Balderrama, Carlos Nunez, Kyle Hendricks, Tyson Hillock, and Dr. Olga Kopp (Utah Valley University)
Faculty Advisor: Kopp, Olga (Utah Valley University, Biology)
Over the last 30 years, the incidence of fungal infections has gradually increased. Mucormycosis is a fungal infection primarily caused by Rhizopus Oryzae. The majority of patients who develop invasive mucormycosis die within 12 weeks of diagnosis. Mucormycosis is commonly treated with an antifungal agent called Amphotericin B (AMB). When used in high concentrations, AMB causes severe side effects such as nephrotoxicity. It has been reported that 99% of microbes exist as biofilm: thus, there is a direct association between mucormycosis and biofilms. Shockwave has been shown to inhibit living bacteria in biofilm, but few studies have focused on the effects of shockwave on fungal biofilm. Previous work in our lab showed that shockwaves were effective in damaging biofilms of R. oryzae; but at the same time helped promote the metabolism of surviving R. oryzae. This study aims to investigate the proteins expressed in fungal biofilms when introduced to different intensities of shockwave coupled with the treatment of AMB. This will be accomplished by culturing sporangiospores and propagating R. oryzae biofilms. Standardized biofilm will be treated with 0.5 µg/mL AMB in 1% DMSO, and/or shockwave treatment of 300 pulses at 0.19 mJ/mm2 energy density to be measured against a control group. The proteins will be extracted, determined by 2D gel electrophoresis, and identified by mass spectrometry. Studying protein expression resulting from combination therapy of extracorporeal shockwave and AMB on R. oryzae biofilm could progress research surrounding the difficulties of mucormycosis treatments. Particularly, research aimed at counteracting the antifungal and antimicrobial resistance contributed by proteins in the fungi's biofilm.